|
Transient Ischemic Attack
|
0.200 |
Biomarker
|
disease |
RGD |
WNK-Cab39-NKCC1 signaling increases the susceptibility to ischemic brain damage in hypertensive rats.
|
27798271 |
2017 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations.
|
21211798 |
2011 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Manipulation of WNK2 expression affects miR-370-mediated cell proliferation and tumor growth.
|
31009242 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
We also explored the functional effect and mechanism of WNK2 on tumor growth and metastasis.
|
31349001 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
WNK2, which is exclusively enriched in neurons, is well known as an anti-proliferative tumor suppressor.
|
27131446 |
2016 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
WNK2 is a tumor suppressor gene expressed in normal brain, and silenced by promoter methylation in gliomas.
|
25596741 |
2015 |
|
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
WNK2 hypermethylation was higher in tumor than in surrounding inflamed tissues and was observed in PanIN lesions as well as in a PDAC mouse model.
|
23912455 |
2014 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Together, these results validate the WNK2 gene as a recurrent target for epigenetic silencing in glia-derived brain tumours and provide first mechanistic evidence for a tumour-suppressing role of WNK2 that is related to Rac1 signalling and tumour cell invasion and proliferation.
|
23035050 |
2013 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.
|
19001526 |
2009 |
|
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
The WNK2 silencing by epigenetic mechanisms was significantly associated (P < 0.01) with a known genetic signature of chemosensitive oligodendroglial tumors, 1p and 19q deletion, in two small but independent tumor sets.
|
17578925 |
2007 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Biofunctional investigations revealed a tumor-suppressor role of WNK2: its inactivation led to ERK1/2 signaling activation in HCC cells, tumor-associated macrophage infiltration, and tumor growth and metastasis.
|
31349001 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
Mechanistic investigation of RAGE downstream in fibroblasts revealed a novel contribution of a mitogen-activated protein kinase kinase kinase (MAPKKK), tumor progression locus 2 (TPL2), which is required for positive regulation of PDAC cell motility through induction of cyclooxygenase 2 (COX2) and its catalyzed production of prostaglandin E2 (PGE2), a strong chemoattractive fatty acid.
|
31046874 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Hematopoietic progenitor kinase 1 (HPK1) belongs to the mitogen activated protein kinase kinase kinase kinase (MAP4K) family of serine/threonine kinases, which have been associated with the incidence and progression of a variety of gastrointestinal malignant tumors in humans.
|
28765906 |
2017 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Mixed-lineage kinase 3 (MLK3), a mitogen-activated protein kinase kinase kinase (MAP3K), has critical roles in metastasis of triple-negative breast cancer (TNBC), in part by regulating paxillin phosphorylation and focal adhesion turnover.
|
28604765 |
2017 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Thus, WNK2 promoter methylation and silencing in gliomas is associated with increased JNK activation and MMP2 expression and activity, thus explaining in part tumor cell invasion potential.
|
25596741 |
2015 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
WNK2 mRNA and protein expressions were lower in PDAC and CP compared with normal tissues both in patients and mouse models.
|
23912455 |
2014 |
|
Meningioma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
The gene encoding protein kinase WNK2 was recently identified to be silenced by promoter hypermethylation in gliomas and meningiomas, suggesting a tumour-suppressor role in these brain tumours.
|
23035050 |
2013 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Together, these results validate the WNK2 gene as a recurrent target for epigenetic silencing in glia-derived brain tumours and provide first mechanistic evidence for a tumour-suppressing role of WNK2 that is related to Rac1 signalling and tumour cell invasion and proliferation.
|
23035050 |
2013 |
|
Meningioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
WNK2 could be reactivated with a methylation inhibitor in IOMM-Lee, a meningioma cell line with a densely methylated WNK2 CpG island and lack of WNK2 expression.
|
19001526 |
2009 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth.
|
17578925 |
2007 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
microRNA-370 Promotes Cell Growth by Targeting WNK2 in Breast Cancer.
|
31009242 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Despite diverse functions in diseases, the prognostic potential of the family of mitogen-activated protein kinase kinase kinase kinase genes in acute myeloid leukemia remains unknown.
|
31522654 |
2019 |
|
Van der Woude syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Administration of LPS significantly increased the levels of mitogen activated protein kinase kinase kinase (MEKK)3 and P-P65 levels, while transfection with miR-NPs significantly reduced the expression of both MEKK3 and P-P65, reflecting that of the control.
|
31226473 |
2019 |